Concurrent chemoradiotherapy with XXXX and @entity900 after incomplete (R1) resection of locally advanced @entity3123 .

@entity1 @entity3123 @entity788 @entity137 @entity882 @entity5 @entity900 @entity1431 @entity3 @entity136
PURPOSE: To analyze, in a prospective clinical trial, the efficacy and @entity137 of concurrent radiotherapy and chemotherapy with @entity136 and @entity900 in @entity1 with incompletely (R1) resected @entity788 . METHODS AND MATERIALS: Between 2000 and 2002, a total of 30 @entity788 @entity1 were treated. Radiotherapy was performed in 15 @entity1 up to a total dose of 45.0 Gy. An additional 15 @entity1 received a total dose of 50.0 Gy according to the International Commission on Radiation Units and Measurements (ICRU) Report 50 reference point (equivalent to 45.0 Gy at the isodose, including 90% covering the former @entity5 area and local lymph nodes). Concurrent with radiotherapy, four applications of @entity136 (300 mg/m(2)) and @entity900 (30 mg/m(2)) were administered. After chemoradiotherapy, @entity1 received four additional courses of @entity136 (1000 mg/m(2)) and @entity900 (50 mg/m(2)) on Days 1 and 15 in a 4-week cycle. RESULTS: The median progression-free survival was 10.6 months, and the median overall survival was 22.8 months. The 1-, 2-, and 3-year survival rate was 81%, 43%, and 26%, respectively. After completion of chemoradiotherapy, distant @entity3 was observed in 14 @entity1 during a median follow-up of 15.0 months (range, 4.6-30.0). One @entity1 developed both local recurrence and distant metastases. Hematologic @entity137 were the most prominent side effects ( @entity1431 Grade 3 and 4 in 53% and 7% and @entity882 Grade 3 and 4 in 33% and 7% of @entity1 , respectively). Grade 3 and 4 @entity137 was not observed. CONCLUSION: Postoperative chemoradiotherapy with @entity136 and @entity900 after incomplete (R1) resection of @entity3123 is safe and feasible. A prolonged progression-free survival suggests high local efficacy, translating into a benefit of overall survival. On the basis of the favorable outcome of @entity1 receiving @entity136 / @entity900 -based chemoradiotherapy, testing this combined treatment strategy appears warranted in a comparative trial.
